LIMMitless trial: Long-term safety and efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis

Risankizumab, a monoclonal antibody that blocks the action of interleukin-23, was evaluated for the treatment of moderate-to-severe plaque psoriasis in the ongoing phase III LIMMitless trial (NCT03047395). There is limited data on the long-term safety and efficacy of risankizumab; in the IMMpulse trial, risankizumab demonstrated greater efficacy compared with apremilast in patients with plaque psoriasis.

Papp et al.¹ recently published the long-term safety and efficacy data from the LIMMitless trial in Journal of American Academy of Dermatology; here, the Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract summarizing the key findings.